Watch CMPX. Know when insiders buy.
One email the day a filing lands. Free.
CMPX
Compass Therapeutics, Inc.
2.05
−0.13 −5.96%
USD · close Sep 10
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
48
WATCH · shorts 48
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $369.2MP/E —DIV YIELD —FCF YIELD -15.27%REV TTM —NET INCOME −$73.4MNET CASH $35.5M52W 1.67 – 6.69SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$27M | −$25.2M | — | -0.13 | −$14.7M | $176K | −$14.9M | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$20.3M | −$18.3M | — | -0.10 | −$17.3M | $82K | −$17.4M | Aug 6 |
| Q4 2025 · Dec 31derived | — | — | — | −$18M | −$15.7M | — | -0.08 | −$13.3M | $0 | −$13.3M | Mar 5 |
| Q3 2025 · Sep 30 | — | — | — | −$15.8M | −$14.3M | — | -0.08 | −$10.8M | $7K | −$10.9M | Nov 5 |
| Q2 2025 · Jun 30 | — | — | — | −$21.1M | −$19.9M | — | -0.14 | −$11.8M | $0 | −$11.8M | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$18M | −$16.6M | — | -0.12 | −$13.2M | $18K | −$13.2M | Aug 6 |
| Q4 2024 · Dec 31derived | — | — | — | −$16.6M | −$15M | — | -0.11 | −$9.2M | $0 | −$9.2M | Mar 5 |
| Q3 2024 · Sep 30 | — | — | — | −$12.2M | −$10.5M | — | -0.08 | −$11.1M | $44K | −$11.1M | Nov 5 |
| Q2 2024 · Jun 30 | — | — | — | −$15M | −$13.1M | — | -0.10 | −$10.8M | $0 | −$10.8M | Nov 5 |
| Q1 2024 · Mar 31 | — | — | — | −$12.8M | −$10.8M | — | -0.08 | −$13.9M | $0 | −$13.9M | Nov 5 |
| Q4 2023 · Dec 31derived | — | — | — | −$15.4M | −$13.4M | — | -0.10 | −$12.4M | $9K | −$12.4M | Feb 27 |
| Q3 2023 · Sep 30 | — | — | — | −$11.9M | −$10M | — | -0.08 | −$5.9M | $10K | −$5.9M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$72.8M | −$66.5M | — | -0.42 | −$49.1M | $25K | −$49.2M | — | — |
| FY2024 · to Dec 31 | — | — | −$56.6M | −$49.4M | — | -0.36 | −$44.9M | $44K | −$44.9M | — | — |
| FY2023 · to Dec 31 | — | — | −$50.4M | −$42.5M | — | -0.33 | −$40.6M | $30K | −$40.6M | — | — |
| FY2022 · to Dec 31 | — | — | −$41.7M | −$39.2M | — | -0.37 | −$34.1M | $212K | −$34.3M | — | — |
| FY2021 · to Dec 31 | — | — | −$81.9M | −$82.2M | — | -1.31 | −$19.7M | $1.6M | −$21.2M | — | — |
| FY2020 · to Dec 31 | — | — | −$27.8M | −$29.5M | — | -0.96 | −$26.8M | $106K | −$26.9M | — | — |
Every number comes from Compass Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.